Antiarrhythmic therapy: clinical pharmacology update.
Currently available antiarrhythmic agents are limited by side effects and the potential for increasing arrhythmias. In addition, drug interactions, altered disposition of drug as a result of changes in protein binding or concomitant disease processes, active metabolites, and poorly defined therapeutic ranges with great interpatient variability are some of the factors which complicate therapy. An awareness of the possible contribution of these factors in the use of antiarrhythmics is invaluable in both the choice of agent and the establishment of an optimum benefit-to-risk ratio for the patient.
D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001711:Biotransformation; D001798:Blood Proteins / Q000378:metabolism; D003692:Delayed-Action Preparations; D004347:Drug Interactions; D004351:Drug Resistance; D006801:Humans; D007700:Kinetics; D011485:Protein Binding
D000889:Anti-Arrhythmia Agents; D001798:Blood Proteins; D003692:Delayed-Action Preparations